novo nordisk's wegovy reduces cardiovascular risk more than lilly's tirzepatide Why weight-loss drug shows promise for heart disease Wegovy Linked To Lower Heart

The SURMOUNT-1 clinical trial showed an average of 16% body weight reduction at the 5mg dose over 72 weeks

This means patients might see better results with injectable semaglutide (like Wegovy or Ozempic) for both blood sugar control and weight loss

For patients managing type 2 diabetes and considering weight loss strategies, we offer personalized consultations to explore the potential off-label use of Tirzepatide

Food and Drug Administration (FDA), the approved dosages for some of the commonly prescribed GLP-1 agonists are as follows: Semaglutide (Ozempic): 0.5 mg, 1 mg, or 2 mg once weekly for type 2 diabetes, and up to 2.4 mg once weekly for chronic weight management (marketed as Wegovy)